Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.37 |
| ▸ | CDK1 | P06493 | 2/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5456964 | 0.86 | CDK2 (0.42) | CDK2CCNA2CCNA1CDK1CDK4 | |
| SCHEMBL15500414 | 0.78 | CDK2 (0.37) | CDK2CCNA2CCNA1CDK1CDK4 | |
| SCHEMBL6402248 | 0.75 | CDK2 (0.40) | CDK2CCNA2CCNA1CDK1CDK4 | |
| SCHEMBL4160357 | 0.74 | CDK2 (0.52) | CDK2CCNA2CCNA1CDK1CDK4 | |
| SCHEMBL8725001 | 0.74 | HSP90AB1 (0.45) | HSP90AB1ABCB1 | |
| SCHEMBL29473573 | 0.74 | CDK2 (0.52) | CDK2CCNA2CCNA1CDK1CDK4 | |
| SCHEMBL2745214 | 0.74 | CDK2 (0.41) | CDK2CCNA2CCNA1CDK1CDK4 | |
| SCHEMBL29693584 | 0.74 | CDK2 (0.41) | CDK2CCNA2CCNA1CDK1CDK4 | |
| Hydrochloric Acid SCHEMBL4410477 | 0.72 | HSP90AB1 (0.43) | HSP90AB1ABCB1 | |
| SCHEMBL5026853 | 0.71 | CDK2 (0.38) | CDK2CCNA2CCNA1CDK1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3398948-A2 | 2,4,6,7-TETRASUBSTITUTED PTERIDINE COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | Janus Biotherapeutics, Inc. (US) | 2018-11-07 | — | — | EP | disclosed |
| US-20170275287-A1 | NOVEL N2, N4, N7, 6-TETRASUBSTITUTED PTERIDINE-2,4,7-TRIAMINE AND 2, 4, 6, 7-TETRASUBSTITUTED PTERIDINE COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | JANUS BIOTHERAPEUTICS, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275287-A1 | NOVEL N2, N4, N7, 6-TETRASUBSTITUTED PTERIDINE-2,4,7-TRIAMINE AND 2, 4, 6, 7-TETRASUBSTITUTED PTERIDINE COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | JANUS BIOTHERAPEUTICS, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| EP-3183251-A1 | NOVEL N2, N4, N7, 6-TETRASUBSTITUTED PTERIDINE-2,4,7-TRIAMINE AND 2, 4, 6, 7-TETRASUBSTITUTED PTERIDINE COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | Janus Biotherapeutics, Inc. (US) | 2017-06-28 | — | — | EP | disclosed |
| WO-2016029077-A1 | NOVEL N2, N4, N7, 6-TETRASUBSTITUTED PTERIDINE-2,4,7-TRIAMINE AND 2, 4, 6, 7-TETRASUBSTITUTED PTERIDINE COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | JANUS BIOTHERAPEUTICS, INC. (US) | 2016-02-25 | — | — | WO | disclosed |
| WO-2016029077-A1 | NOVEL N2, N4, N7, 6-TETRASUBSTITUTED PTERIDINE-2,4,7-TRIAMINE AND 2, 4, 6, 7-TETRASUBSTITUTED PTERIDINE COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | JANUS BIOTHERAPEUTICS, INC. (US) | 2016-02-25 | — | — | WO | disclosed |
| US-9221822-B2 | Thiazolopyrimidine modulators as immunosuppressive agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K. U. LEUVEN R&D (BE) | 2015-12-29 | — | — | US | disclosed |
| EP-2923734-A1 | Purine analogues and their use as immunosuppressive agents | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2015-09-30 | — | — | EP | disclosed |
| US-20150038494-A1 | Thiazolopyrimidine Modulators as Immunosuppressive Agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2015-02-05 | — | — | US | disclosed |
| US-8901132-B2 | Thiazolopyrimidine modulators as immunosuppressive agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-12-02 | — | — | US | disclosed |
| WO-2012064674-A1 | MATERIALS AND METHODS FOR IMMUNOASSAY OF PTERINS | ABBOTT LABORATORIES (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20120115244-A1 | MATERIALS AND METHODS FOR IMMUNOASSAY OF PTERINS | ABBOTT LABORATORIES (US) | 2012-05-10 | — | — | US | disclosed |
| EP-0759927-B1 | PTERIDINE NUCLEOTIDE ANALOGS AS FLUORESCENT DNA PROBES | US GOV HEALTH & HUMAN SERV (US) | 1998-06-24 | — | — | EP | disclosed |
| US-5612468-A | GENETIC ENGINEERING | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-03-18 | — | — | US | disclosed |
| EP-0759927-A1 | PTERIDINE NUCLEOTIDE ANALOGS AS FLUORESCENT DNA PROBES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-03-05 | — | — | EP | disclosed |
| US-5525711-A | MONOMERS FOR DNA AMPLIFICATION PROCEDURES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-06-11 | — | — | US | disclosed |
| WO-1995031469-A1 | PTERIDINE NUCLEOTIDE ANALOGS AS FLUORESCENT DNA PROBES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038494-A1 | Thiazolopyrimidine Modulators as Immunosuppressive Agents | TPMT, STAT6, IL4 | CDK2 440/4885CCNA2 1226/4885CCNA1 1171/4885 |
| US-20120115244-A1 | MATERIALS AND METHODS FOR IMMUNOASSAY OF PTERINS | SPR, CD68, CMKLR2 | CDK2 3030/4885CCNA2 2002/4885CCNA1 1520/4885 |
| US-20170275287-A1 | NOVEL N2, N4, N7, 6-TETRASUBSTITUTED PTERIDINE-2,4,7-TRIAMINE AND 2, 4, 6, 7-TETRASUBSTITUTED PTERIDINE COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | TLR7, C5, CD4 | CDK2 355/4885CCNA2 264/4885CCNA1 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.